

27 February 2025

PureTech Health plc

PDMR Notifications

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases, announces that awards of restricted share units ("RSUs") granted by PureTech on 18 May 2022 to certain directors and other persons discharging managerial responsibilities ("PDMRs") pursuant to its Performance Share Plan ("PSP") vested on 24 February 2025 following satisfaction of performance conditions measured over the three year period to 31 December 2024.

Each PDMR received vested ordinary shares (after deduction of shares for payroll taxes) on 26 February 2025. The market price per ordinary share in the Company used to calculate the amount payable to the PDMRs and the amount of shares to be issued to PDMRs was 144.6 pence, being the average closing price of the Company's shares over the three-trading day period immediately preceding the vesting date, and the exchange rate used to calculate the cash payment and amount of share settlement was £1: 1.26.

The Company's total issued ordinary share capital is 257,927,489 shares after the share issuance to the PDMRs, 17,738,040 shares of which are held in treasury by the Company.

PDMR Notification

The information contained in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.

Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated											
a)	Name	Bharatt Chowrira Eric Elenko										
2	Reason for the notification											
a)	Position/status	Bharatt Chowrira - Chief Executive Officer Eric Elenko - President										
b)	Initial notification/Amendment	Initial Notification										
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor											
a)	Name	PureTech Health plc										
b)	LEI	213800LVPDNO2Z9T9I39										
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted											
a)	Description of the financial instrument, type of instrument	Ordinary Shares of PureTech Health plc ISIN GB00BY2Z0H74										
b)	Nature of the transaction	Issuance of ordinary shares in net settlement of certain vested RSUs under the PureTech Health Performance Share Plan, after retentions in respect of payroll taxes.										
c)	Price(s) and volume(s)	<table><tr><th>Recipient</th><th>Price</th><th>Amount</th></tr><tr><td>Bharatt Chowrira</td><td>0.01 GBP</td><td>108,103 ordinary shares</td></tr><tr><td>Eric Elenko</td><td>0.01 GBP</td><td>118,710 ordinary shares</td></tr></table>		Recipient	Price	Amount	Bharatt Chowrira	0.01 GBP	108,103 ordinary shares	Eric Elenko	0.01 GBP	118,710 ordinary shares
Recipient	Price	Amount										
Bharatt Chowrira	0.01 GBP	108,103 ordinary shares										
Eric Elenko	0.01 GBP	118,710 ordinary shares										
d)	Aggregated information - Aggregated volume - Price	<table><tr><th>Price</th><th>Aggregate Volume</th></tr><tr><td>0.01 GBP</td><td>226,813 ordinary shares</td></tr></table>		Price	Aggregate Volume	0.01 GBP	226,813 ordinary shares					
Price	Aggregate Volume											
0.01 GBP	226,813 ordinary shares											
e)	Date of the transaction	26 February 2025										
f)	Place of the transaction	London Stock Exchange (XLON)										

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit [www.puretechhealth.com](http://www.puretechhealth.com) or connect with us on X (formerly Twitter) @puretechh.

Contact:

**PureTech**

Investor Relations

IR@puretechhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHPPUBGUPAGCM